Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
Shortages of crucial cancer medications continue to impact US healthcare

Shortages of crucial cancer medications continue to impact US healthcare

Gene removal makes engineered immune cells more effective against osteosarcoma

Gene removal makes engineered immune cells more effective against osteosarcoma

Tumor-secreted protein makes lung blood vessels leaky to promote metastasis

Tumor-secreted protein makes lung blood vessels leaky to promote metastasis

Obscure X chromosome protein emerges as key driver in several cancers

Obscure X chromosome protein emerges as key driver in several cancers

Advanced synthetic grafting material fights bone cancer and prevents infection

Advanced synthetic grafting material fights bone cancer and prevents infection

New synthetic grafting material kills bone cancer and regenerates bone

New synthetic grafting material kills bone cancer and regenerates bone

UCLA researcher receives grant for advanced osteosarcoma immunotherapy

UCLA researcher receives grant for advanced osteosarcoma immunotherapy

Active β-catenin promotes aggressive spread of childhood bone cancer

Active β-catenin promotes aggressive spread of childhood bone cancer

New PET imaging platform improves osteosarcoma surgery precision

New PET imaging platform improves osteosarcoma surgery precision

New biomarker predicts therapy response for hard-to-treat childhood cancers

New biomarker predicts therapy response for hard-to-treat childhood cancers

Restoring ADAR2 enzyme reduces metastatic spread in osteosarcoma

Restoring ADAR2 enzyme reduces metastatic spread in osteosarcoma

WSU researchers use spice extracts to enhance medical bone implants

WSU researchers use spice extracts to enhance medical bone implants

NCCN conference highlights advances in global cancer care strategies

NCCN conference highlights advances in global cancer care strategies

Study reveals new dual role of ezrin in osteosarcoma

Study reveals new dual role of ezrin in osteosarcoma

New CAR-T cell therapy shows promise for treating osteosarcoma

New CAR-T cell therapy shows promise for treating osteosarcoma

Childhood cancer survival varies by tumor stage at diagnosis

Childhood cancer survival varies by tumor stage at diagnosis

Blocking p300 restores chemotherapy sensitivity in resistant tumors

Blocking p300 restores chemotherapy sensitivity in resistant tumors

FIU's personalized cancer treatment shows promise

FIU's personalized cancer treatment shows promise

Bifunctional biomaterials for postoperative management of osteosarcoma

Bifunctional biomaterials for postoperative management of osteosarcoma

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.